SELLAS REGAL Trial Reaches 80th Death Event, Triggering Final Analysis
Photo: TokenPost
SELLAS Life Sciences Group, Inc. said Oct. 28 that its Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia reached its prespecified 80th death event, triggering a final analysis. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
